Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR6 | P51684 | 3/20 | 0.44 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 11/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3388537 | 0.83 | CCR6 (0.55) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL13309094 | 0.76 | POLB (0.48) | ALDH1A1PKMLMNAGAAHTT | |
| SCHEMBL3390120 | 0.75 | ALDH1A1 (0.42) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL3390111 | 0.75 | ALDH1A1 (0.42) | CCR6CCNKCCNA2CDK2CDK12 | |
| SCHEMBL3390593 | 0.75 | POLB (0.41) | ALDH1A1PKMCYP3A4LMNAGAA | |
| SCHEMBL2790371 | 0.75 | HCRTR1 (0.47) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL3390604 | 0.75 | HCRTR1 (0.47) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL13309233 | 0.72 | HCRTR1 (0.43) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL3390663 | 0.71 | POLB (0.53) | ALDH1A1PKMLMNAGAAHTT | |
| SCHEMBL3386500 | 0.71 | POLB (0.50) | ALDH1A1PKMLMNAGAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| US-20100144760-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | US | disclosed |
| WO-2010063663-A1 | N-{[(IR,4S,6R-3-(2-PYRIDINYLCARBONYL)-3-AZABICYCLO [4.1.0]HEPT-4-YL] METHYL}-2-HETEROARYLAMINE DERIVATIVES AND USES THEREOF | GLAXO GROUP LIMITED (GB) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144760-A1 | NOVEL COMPOUNDS | HTR3B, HTR1B, HTR2B | CCR6 1784/4885CCNK 1049/4885CCNA2 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.